The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index ®.
The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times the inverse (-2x) of the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. It is non-diversified.
Latest BIS News
No recent news for ProShares UltraShort Nasdaq Biotechnology.
|1 month||-2.18%|| ||3 years||-55.31%|
|3 months||-23.22%|| ||5 years||--|
|1 year||-52.60%|| ||Since inception||-48.31%|
|Open day’s range||14.10 – 14.73|
|Net asset value (NAV)||13.92 (07/30/2014)|
|Average volume (3 months)||425,179|
Data as of 3:59pm ET, 07/31/2014
Peer Comparisonvs. Trading-inverse equity ETFs
|Performance 5-yr return||--||-35.97%|
|Expense Gross exp ratio||2.91%||0.96%|
|Risk 5 year sharpe ratio||--||-1.31|
|Average market cap||--||$63.2B|
|Dividend / Share||--||0.38%|
|SH ProShares Short S&P500|
|SDS ProShares UltraShort S&P500|
|SPXU ProShares UltraPro Short S&P500|
Top 5 Sectors
Top 10 Holdings